Skip to main content
. 2020 Mar 24;2(2):73–90. doi: 10.36628/ijhf.2020.0002

Figure 3. Levels of NT-proBNP over 8 weeks according to drug treatment in PIONEER-HF. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, −46.7% vs. −25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% CI, 0.63–0.81; p<0.001). Data from reference 32 with permission.

Figure 3

CI = confidence interval; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PIONEER-HF = Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode.